Technology Available for Industry-Academia Collaboration or Technology Licensing. "**DBPR22998:** IsoQC inhibitor targeting CD47-SIRP $\alpha$  "Do not eat me" cancer immune checkpoint"

Date: 2022.11.18

#### 1. Title:

NHRI technology, "DBPR22998: IsoQC inhibitor targeting CD47-SIRPα "Do not eat me" cancer immune checkpoint" (abbreviated as "**The Technology**") available for industry-academia collaboration or technology licensing.

## 2. Description:

DBPR22998 is an orally bioavailable small molecule isoQC inhibitor that modulate CD47-SIRPα "Do not eat me" cancer immune checkpoint activity through targeting post translational modification process of CD47 protein synthesis. DBPR22998 demonstrated potent isoQC inhibitory activity in vitro and anti-tumor efficacy in combination with therapeutic antibodies and immune checkpoint inhibitors in vivo. In addition, DBPR22998 did not cause hematological toxicity as anti-CD47 antibody therapeutics in clinical development.

- 3. Potential collaboration partner qualifications:
- (1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
- (2) better to have related experience and skills for developing **The Technology**
- (3) better to have experience of international collaboration and clinical trial
- (4) be willing to provide long-term investment

### 4. Registration:

Please contact to Ms. Wan-Ping Hsieh (email: <a href="wanping@nhri.edu.tw">wanping@nhri.edu.tw</a>) or Ms. Wen-Chuan Hsieh (email: <a href="wenchuan@nhri.edu.tw">wenchuan@nhri.edu.tw</a>). Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan.

### 5. Other:

- (1) If **The Technology** has been exclusively licensed, this announcement will automatically invalid.
- (2) NHRI retains the right to modify and terminate this announcement.

(3) For detailed status of **The Technology**, please contact to the case officer.

# Attachments:

- I. Announcement
- II. <u>Technology Transfer Vendor Qualification Form</u>
- III. Industry-Academia Collaboration Proposal